Skip to main content
Have a personal or library account? Click to login
Interpreting the serotonin blood pressure paradox: An updated integrative framework for hypertension Cover

Interpreting the serotonin blood pressure paradox: An updated integrative framework for hypertension

Open Access
|Nov 2026
Read online

References

  1. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. doi:10.1093/eurheartj/ehae178.
  2. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–237. doi:10.1038/s41581-019-0244-2.
  3. Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–388. doi:10.1124/pr.111.004697.
  4. Vanhoutte PM. Serotonin and the blood-vessel wall. J Hypertens Suppl. 1986;4(5):S112–S115.
  5. Frishman WH, Grewall P. Serotonin and the heart. Ann Med. 2000;32(3):195–209. doi:10.3109/07853890008998827.
  6. Soslau G. Cardiovascular serotonergic system: evolution, receptors, transporter, and function. J Exp Zool A Ecol Integr Physiol. 2022;337(2):115–127. doi:10.1002/jez.2554.
  7. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–276. doi:10.1016/j.cell.2015.02.047.
  8. Bader M. Serotonylation: serotonin signaling and epigenetics. Front Mol Neurosci. 2019;12:288. doi:10.3389/fnmol.2019.00288.
  9. Williams RB, Bishop GD, Haberstick BC, Smolen A, Brummett BH, Siegler IC, et al. Population differences in associations of serotonin transporter promoter polymorphism (5HTTLPR) di- and triallelic genotypes with blood pressure and hypertension prevalence. Am Heart J. 2017;185:110–122. doi:10.1016/j.ahj.2016.12.013.
  10. Zhang Y, Wang N, Zhang L, Zhuang Y, Xin Q, Gu X, et al. Serotonin (5-hydroxytryptamine): metabolism, signaling, biological functions, diseases, and emerging therapeutic opportunities. MedComm. 2025;6(9):e70383. doi:10.1002/mco2.70383.
  11. Mercado CP, Kilic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv. 2010;10(4):231–241. doi:10.1124/mi.10.4.6.
  12. Kubo T, Taguchi K, Ozaki S, Amano M, Ishizuka T. 8-OH-DPAT-induced hypotensive action and sympathoexcitatory neurons in the rostral ventrolateral medulla of the rat. Brain Res Bull. 1995;36(4):405–411. doi:10.1016/0361-9230(94)00221-L.
  13. Comet MA, Bernard JF, Hamon M, Laguzzi R, Sevoz-Couche C. Activation of nucleus tractus solitarius 5-HT2A but not other 5-HT2 receptor subtypes inhibits the sympathetic activity in rats. Eur J Neurosci. 2007;26(2):345–354. doi:10.1111/j.1460-9568.2007.05673.x.
  14. Merahi N, Orer HS, Laporte AM, Gozlan H, Hamon M, Laguzzi R. Baroreceptor reflex inhibition induced by the stimulation of serotonin3 receptors in the nucleus tractus solitarius of the rat. Neuroscience. 1992;46(1):91–100. doi:10.1016/0306-4522(92)90011-P.
  15. Spinieli RL, Cornelius-Green J, Cummings KJ. A serotonin-deficient rat model of neurogenic hypertension: influence of sex and sympathetic vascular tone. J Neurophysiol. 2022;128(5):1199–1206. doi:10.1152/jn.00358.2022.
  16. Mandal AK, Kellar KJ, Friedman E, Pineo SV, Hamosh P, Gillis RA. Importance of central nervous system serotonin-1A receptors for mediating the hypotensive effect of urapidil. J Pharmacol Exp Ther. 1989;251(2):563–570. doi:10.1016/S0022-3565(25)20845-X.
  17. Bielen E, Fagard R, Staessen J, Lijnen P, Van Hoof R, Amery A. Urapidil-induced hemodynamic changes in humans. Am J Cardiol. 1989;64(7):16D–21D. doi:10.1016/0002-9149(89)90690-5.
  18. Tanaka N, Nakamura E, Ohkura M, Kuwabara M, Yamashita A, Onitsuka T, et al. Both 5-hydroxytryptamine 5-HT2A and 5-HT1B receptors are involved in the vasoconstrictor response to 5-HT in the human isolated internal thoracic artery. Clin Exp Pharmacol Physiol. 2008;35(7):836–840. doi:10.1111/j.1440-1681.2008.04933.x.
  19. Li N, Wallen NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis. 1997;8(8):517–523. doi:10.1097/00001721-199711000-00006.
  20. Bruning TA, van Zwieten PA, Blauw GJ, Chang PC. No functional involvement of 5-hydroxytryptamine1A receptors in nitric oxide-dependent dilatation caused by serotonin in the human forearm vascular bed. J Cardiovasc Pharmacol. 1994;24(3):454–461. doi:10.1097/00005344-199409000-00014.
  21. Gonzalez-Pons R, McRae K, Thompson JM, Watts SW. 5-HT7 receptor restrains 5-HT-induced 5-HT2A mediated contraction in the isolated abdominal vena cava. J Cardiovasc Pharmacol. 2021;78(2):319–327. doi:10.1097/FJC.0000000000001057.
  22. Cameron HA, Waller PC, Ramsay LE. Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta-adrenoceptor antagonist. Br J Clin Pharmacol. 1987;24(6):705–711. doi:10.1111/j.1365-2125.1987.tb03235.x.
  23. Donnelly R, Elliott HL, Meredith PA, Reid JL. Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics. Br J Clin Pharmacol. 1987;24(5):599–606. doi:10.1111/j.1365-2125.1987.tb03218.x.
  24. Hosie J, Stott DJ, Robertson JI, Ball SG. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. J Cardiovasc Pharmacol. 1987;10(Suppl 3):S86–S88. doi:10.1097/00005344-198700103-00022.
  25. Reigstad CS, Salmonson CE, Rainey JF 3rd, Szurszewski JH, Linden DR, Sonnenburg JL, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J. 2015;29(4):1395–1403. doi:10.1096/fj.14-259598.
  26. Yang T, Maki KA, Marques FZ, Cai J, Joe B, Pepine CJ, et al. Hypertension and the gut microbiome: a Science Advisory From the American Heart Association. Hypertension. 2025;82(9):e160–e170. doi:10.1161/HYP.0000000000000247.
  27. Welathanthree M, Keating DJ, Macefield VG, Carnevale D, Marques FZ, Muralitharan RR. Cross-talk between microbiota-gut-brain axis and blood pressure regulation. Clin Sci (Lond). 2025;139(9):431–447. doi:10.1042/CS20240787.
  28. Sree Kumar H, Zubcevic J. Host-microbiota interactions regulate gut serotonergic signaling: implications for hypertension. Am J Physiol Cell Physiol. 2025;329(6):C1742–C1751. doi:10.1152/ajpcell.00608.2025.
  29. Rieder M, Gauchel N, Bode C, Duerschmied D. Serotonin: a platelet hormone modulating cardiovascular disease. J Thromb Thrombolysis. 2021;52(1):42–47. doi:10.1007/s11239-020-02331-0.
  30. Brand T, Anderson GM. The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis. Clin Chem. 2011;57(10):1376–1386. doi:10.1373/clinchem.2011.163824.
  31. von Volkmann HL, Brønstad I, Fiskerstrand T, Gudbrandsen OA. Comparison of pre-analytical conditions for quantification of serotonin in platelet-poor plasma. Pract Lab Med. 2019;17:e00136. doi:10.1016/j.plabm.2019.e00136.
  32. Pillalamarri S, Anderson GM. The continued mismeasurement of plasma serotonin: a systematic review. Biomed Chromatogr. 2025;39(3):e70016. doi:10.1002/bmc.70016.
  33. Kamal LA, Le Quan-Bui KH, Meyer P. Decreased uptake of 3H-serotonin and endogenous content of serotonin in blood platelets in hypertensive patients. Hypertension. 1984;6(4):568–573. doi:10.1161/01.HYP.6.4.568.
  34. Biondi ML, Agostoni A, Marasini B. Serotonin levels in hypertension. J Hypertens Suppl. 1986;4(1):S39–S41.
  35. Nityanand S, Tekwani BL, Chandra M, Shanker K, Singh BN. Kinetics of serotonin in platelets in essential hypertension. Life Sci. 1990;46(5):367–372. doi:10.1016/0024-3205(90)90016-K.
  36. Fetkovska N, Pletscher A, Ferracin F, Amstein R, Buhler FR. Impaired uptake of 5-hydroxytryptamine platelet in essential hypertension: clinical relevance. Cardiovasc Drugs Ther. 1990;4(Suppl 1):105–109. doi:10.1007/BF00053439.
  37. Jafri SM, Chandra N, Dhawan S, Soni D, Chandra M, Shanker K. Factors influencing platelet serotonin uptake in essential hypertension. Int J Cardiol. 1992;34(3):327–333. doi:10.1016/0167-5273(92)90031-W.
  38. Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, Mehta JL, et al. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem. 2007;102(1):206–215. doi:10.1111/j.1471-4159.2007.04542.x.
  39. Tomoda F, Takata M, Oh-Hashi S, Ueno H, Yasumoto K, Iida H, et al. Altered renal response to enhanced endogenous 5-hydroxytryptamine after tryptophan administration in essential hypertension. Clin Sci (Lond). 1992;82(5):551–557. doi:10.1042/cs0820551.
  40. Hirose M, Tomoda F, Koike T, Yamazaki H, Ohara M, Liu H, et al. Imbalance of renal production between 5-hydroxytryptamine and dopamine in patients with essential hypertension complicated by microalbuminuria. Am J Hypertens. 2013;26(2):227–233. doi:10.1093/ajh/hps008.
  41. Choi JR, Jeon M, Koh SB. Association between serotonin 2A receptor (HTR2A) genetic variations and risk of hypertension in a community-based cohort study. BMC Med Genet. 2020;21(1):5. doi:10.1186/s12881-019-0927-3.
  42. Liolitsa D, Powell JF, Prince M, Lovestone S. Association study of the 5-HT2A receptor gene polymorphism, T102C and essential hypertension. J Hum Hypertens. 2001;15(5):335–339. doi:10.1038/sj.jhh.1001177.
  43. Calvi A, Fischetti I, Verzicco I, Belvederi Murri M, Zanetidou S, Volpi R, et al. Antidepressant drugs effects on blood pressure. Front Cardiovasc Med. 2021;8:704281. doi:10.3389/fcvm.2021.704281.
  44. Zhong Z, Wang L, Wen X, Liu Y, Fan Y, Liu Z. A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials. Neuropsychiatr Dis Treat. 2017;13:2781–2796. doi:10.2147/NDT.S141832.
  45. Zhang L, Li G, Liu M. A meta-analysis on the association between SSRIs and blood pressure in patients with CVD and depression. J Affect Disord. 2023;340:181–188. doi:10.1016/j.jad.2023.08.032.
  46. Pillinger T, Arumuham A, McCutcheon RA, D'Ambrosio E, Basdanis G, Branco M, et al. The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis. Lancet. 2025;406(10515):2063–2077. doi:10.1016/S0140-6736(25)01293-0.
  47. Walther DJ, Peter JU, Winter S, Holtje M, Paulmann N, Grohmann M, et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell. 2003;115(7):851–862. doi:10.1016/S0092-8674(03)01014-6.
  48. Watts SW, Priestley JRC, Thompson JM. Serotonylation of vascular proteins important to contraction. PLoS One. 2009;4(5):e5682. doi:10.1371/journal.pone.0005682.
  49. Guilluy C, Rolli-Derkinderen M, Tharaux PL, Melino G, Pacaud P, Loirand G. Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem. 2007;282(5):2918–2928. doi:10.1074/jbc.M604195200.
  50. Liu Y, Wei L, Laskin DL, Fanburg BL. Role of protein transamidation in serotonin-induced proliferation and migration of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2011;44(4):548–555. doi:10.1165/rcmb.2010-0078OC.
  51. Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L, et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med. 2009;179(12):1151–1158. doi:10.1164/rccm.200805-691OC.
  52. Stier CT Jr, McKendall G, Itskovitz HD. Serotonin formation in nonblood-perfused rat kidneys. J Pharmacol Exp Ther. 1984;228(1):53–56. doi:10.1016/S0022-3565(25)21590-7.
  53. Stier CT Jr, Itskovitz HD. Formation of serotonin by rat kidneys in vivo. Proc Soc Exp Biol Med. 1985;180(3):550–557. doi:10.3181/00379727-180-42216.
  54. Takahashi T, Hisa H, Satoh S. Serotonin-induced renin release in the dog kidney. Eur J Pharmacol. 1991;193(3):315–320. doi:10.1016/0014-2999(91)90145-G.
  55. Oleshchuk OM, Chornomydz AV. Endothelial dysfunction: problematic issues of definition and classification. Achiev Clin Exp Med. 2025;3:170–179. doi:10.11603/1811-2471.2025.v.i3.15567.
  56. Vrints CJ, Bult H, Bosmans J, Herman AG, Snoeck JP. Paradoxical vasoconstriction as result of acetylcholine and serotonin in diseased human coronary arteries. Eur Heart J. 1992;13(6):824–831. doi:10.1093/oxfordjournals.eurheartj.a060264.
  57. Forstermann U, Mugge A, Bode SM, Frolich JC. Response of human coronary arteries to aggregating platelets: importance of endothelium-derived relaxing factor and prostanoids. Circ Res. 1988;63(2):306–312. doi:10.1161/01.RES.63.2.306.
  58. Watanabe T, Pakala R, Katagiri T, Benedict CR. Angiotensin II and serotonin potentiate endothelin-1-induced vascular smooth muscle cell proliferation. J Hypertens. 2001;19(4):731–739. doi:10.1097/00004872-200104000-00010.
  59. Dzau VJ, Hodgkinson CP. Precision hypertension. Hypertension. 2024;81(4):702–708. doi:10.1161/HYPERTENSIONAHA.123.21710.
  60. Cseh D, Yasmin, McDonnell BJ, Maki-Petaja KM, Simonian T, Cockcroft JR, et al. Phenotypes of hypertension: impact of age and sex on hemodynamic mechanisms. J Am Heart Assoc. 2025;14(17):e042096. doi:10.1161/JAHA.125.042096.
  61. Rauseo E, Salih AM, Cooper J, Abdulkareem M, Banerji CRS, Chadalavada S, et al. Clinical phenotypes in hypertension: a data-driven approach to risk stratification. Hypertension. 2026;83(6):e25187. doi:10.1161/HYPERTENSIONAHA.125.25187.
  62. Xu X, Khunsriraksakul C, Eales JM, Rubin S, Scannali D, Saluja S, et al. Genetic imputation of kidney transcriptome, proteome and multi-omics illuminates new blood pressure and hypertension targets. Nat Commun. 2024;15(1):2359. doi:10.1038/s41467-024-46132-y.
DOI: https://doi.org/10.2478/rjc-2026-0032 | Journal eISSN: 2734-6382 | Journal ISSN: 1220-658X
Language: English
Published on: Nov 6, 2026
Published by: Romanian Society of Cardiology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Oleksandra Oleshchuk, Yurii Chornomydz, Andrii Chornomydz, published by Romanian Society of Cardiology
This work is licensed under the Creative Commons Attribution 4.0 License.